European regulators cleared Fractyl Health’s clinical test of a GLP-1 gene therapy, placing the company at the center of the race to deliver “one-and-done” alternatives to chronic GLP-1 injections and pills. The approval supports a move toward durable metabolic control without the ongoing dosing burden. For Fractyl, the regulatory step changes the timeline for clinical execution and strengthens the company’s positioning in obesity and related cardiometabolic markets. For competitors, it raises the probability that gene-based approaches will be validated alongside small molecules and peptides. The key watch item is how regulators and trial design will evaluate durability, tissue delivery, and safety endpoints for a metabolic gene therapy platform.